Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities
CompletedOBSERVATIONAL
Enrollment
246
Participants
Timeline
Start Date
August 31, 2011
Primary Completion Date
May 31, 2016
Study Completion Date
May 31, 2016
Conditions
Moderate to Severe Plaque Psoriasis
All Listed Sponsors
collaborator
Raffeiner GmbH
INDUSTRY
lead
AbbVie (prior sponsor, Abbott)
INDUSTRY
NCT01401452 - Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities | Biotech Hunter | Biotech Hunter